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Glial cell line-derived neurotrophic factor (GDNF) exerts a notable protective effect on dopaminergic neurons in rodent and primate
models of Parkinson’s disease (PD). The clinical applicability of this therapy is, however, hampered by the need of a durable and stable
GDNF source allowing the safe and continuous delivery of the trophic factor into the brain parenchyma. Intrastriatal carotid body (CB)
autografting is a neuroprotective therapy potentially useful in PD. It induces long-term recovery of parkinsonian animals through a
trophic effect onnigrostriatal neuronsandcauses ameliorationof symptoms in somePDpatients.Moreover, theadult rodentCBhasbeen
shown to express GDNF. Here we show, using heterozygous GDNF/lacZ knock-out mice, that unexpectedly CB dopaminergic glomus, or
type I, cells are the source of CBGDNF. Among the neural or paraneural cells tested, glomus cells are those that synthesize and release the
highest amount ofGDNF in the adult rodent (asmeasuredby standard and in situELISA). Furthermore,GDNFexpressionby glomus cells
is maintained after intrastriatal grafting and in CB of aged and parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated
animals. Thus, glomus cells appear to be prototypical abundant sources of GDNF, ideally suited to be used as biological pumps for the
endogenous delivery of trophic factors in PD and other neurodegenerative diseases.
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Introduction
Neurotrophic factors have emerged recently as promising thera-
peutic tools for neurodegenerative disorders because they can
prevent neuronal death. The impairment of motor functions
characteristic of Parkinson’s disease (PD) results primarily from
the progressive degeneration of dopaminergic neurons in the
substantia nigra (SN) projecting to the striatum. Thus, in parallel
with work focused on transplantation of dopamine-secreting
cells, several studies have promoted the use of the dopaminotro-
phic glial cell line-derived neurotrophic factor (GDNF) (Lin et
al., 1993) to treat PD. In rodent and primate models of PD,
GDNF has been shown to be neuroprotective and to induce fiber
outgrowth when administered into the ventricles or directly into
the brain parenchyma (Tomac et al., 1995; Gash et al., 1996;
Bjo¨rklund et al., 1997; Choi-Lundberg et al., 1997; Rosenblad et
al., 1998; Kordower et al., 2000; Akerud et al., 2001; Grondin et
al., 2002). The applicability of GDNF therapy to PD patients is
being assayed in clinical trails, and the method of delivery has
become a critical issue (Gill et al., 2003; Nutt et al., 2003; Kirik et
al., 2004). The variables that determine the efficacy of GDNF to
ameliorate PD in animal models and humans remain unclear.
The use of carotid body (CB) tissue to treat PD has been
suggested because it is composed of glomus cells, which contain
and secrete high levels of dopamine and, in addition, are resistant
to hypoxia (Lopez-Barneo et al., 2001). Intrastriatal transplanta-
tion of CB cells has been shown to produce a marked ameliora-
tion of experimental parkinsonism in rodents (Espejo et al., 1998;
Hao et al., 2002; Toledo-Aral et al., 2003; Shuukla et al., 2004) and
monkeys (Luquin et al., 1999). A recent safety study has shown
that CB autografts can induce significant beneficial clinical effects
on PD patients (Arjona et al., 2003). Observations in rodents
have, however, indicated that CB transplants improve parkinso-
nian symptoms because of a trophic effect on the nigrostriatal
neurons, which are encouraged to reinnervate the striatum,
rather than because of the release of dopamine from the trans-
planted cells. These experiments have also demonstrated that
GDNF is expressed in the CB of adult mice (Toledo-Aral et al.,
2003).
The present research was undertaken to identify the source of
GDNF produced in the CB and to estimate the level of GDNF
synthesized in the CB compared with other neural or paraneural
tissues previously or currently used for transplantation studies in
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PD. We also examined whether GDNF production is maintained
after intrastriatal CB grafting and in CB of aged and parkinsonian
[1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated]
animals. Finally, we investigated whether nonspecific sources of
GDNF are activated after brain injury produced by the transplanta-
tion surgery. We show that CB GDNF is produced in dopaminergic
glomus cells. Among the cells tested, glomus cells are those with the
higher capacity to produce and secrete GDNF in the adult rodent,
maintaining a stable phenotype once they are transplanted in the
striatum. Glomus cells appear to be an ideal prototypical device for
the synergistic endogenous delivery of GDNF and other trophic fac-
tors in the brain parenchyma.
Materials andMethods
Animal care and chronic MPTP treatment. Heterozygous GDNF/lacZ
mice (Sa´nchez et al., 1996), C57BL/6 mice and Wistar rats were housed at
a regulated temperature (22 1°C) in a 12 h light/dark cycle, with access
ad libitum to food and water. Animal surgery and killing were performed
under chloral hydrate anesthesia (490 mg/kg for mice and 350 mg/kg for
rats, i.p.). Heterozygous GDNF/lacZ mice (2 months old) were rendered
parkinsonian by the subcutaneous administration (20 mg/kg) of MPTP
(Sigma, St. Louis, MO) twice per week during 3 months. All experiments
were performed according to the animal care guidelines of the European
Communities Council (86/609/EEC). The study was approved by the
Committee on Animal Research at the University of Seville, University
Hospital Virgen del Rocı´o.
Histological analyses. Mouse tissues were removed from anesthetized
animals and immediately fixed overnight at 4°C with 4% paraformalde-
hyde in PBS. Slices 40 –100 m thick were cut with a Vibratome (Vi-
bratome, St. Louis, MO). Tyrosine hydroxylase (TH) immunohistologi-
cal detection was as described previously (Toledo-Aral et al., 2003), using
a polyclonal anti-TH antibody (1:1000; Pel-Freez, Roger, AR) and a sec-
ondary biotin conjugated anti-rabbit antibody (1:200; Pierce, Rockport,
IL). For the histological detection of GDNF expression, we used het-
erozygous GDNF/lacZ mice 1–17.5 months old and the 5-bromo-4-
chloro-3-indolyl--D-galactopyranoside (X-gal) staining (Sa´nchez et al.,
1996). For colocalization studies, TH immunohistochemistry was per-
formed after X-gal staining. Quantification of GDNF expression in CBs of
aged, MPTP-treated, and control heterozygous GDNF/lacZ mice was done
by counting the total number of blue–green X-gal dots. For that purpose, all
of the CB-containing slices were photographed and digitized in series chang-
ing the focal plane in 8m steps. CB volume was calculated from the thick-
ness of the CB-containing slices, and the CB area in each section was ob-
tained by computer using the appropriate tools of Canvas 6.0 (Deneba
Systems, Miami, FL). MPTP-induced neuronal damage in heterozygous
GDNF/lacZ mice was roughly estimated by counting TH-positive cells of the
substantia nigra in mesencephalic coronal sections (10 per animal). This
value was compared with the one obtained using the same procedure in
control (saline-injected) animals. Values are given as mean  SEM. The
statistical significance of differences among parameters was considered at a
value of p 0.05 (Student’s t test).
Immunocytochemistry in mice carotid body primary cell cultures. CBs
were removed from carotid bifurcations of heterozygous GDNF/lacZ
mice (4 – 6 weeks old). Immediately thereafter, the CBs were dissected in
Tyrode’s solution at 4°C with oxygen saturation. CBs were then incu-
bated in Tyrode’s solution containing 0.6 mg/ml collagenase type II
(Sigma) and 0.3 mg/ml trypsin (Sigma) for 30 min at 37°C with shaking
and mechanic disruption every 10 min using fire-polished Pasteur pi-
pettes. After the enzymatic treatment, dissociated CB cells were centri-
fuged for 5 min at 200 g and 4°C. Afterward, the pellet was resuspended
in DMEM (Invitrogen, Grand Island, NY) supplemented with 10% fetal
bovine serum (BioWhittaker, Verviers, Belgium), 1% penicillin/strepto-
mycin (BioWhittaker), 1% L-glutamine (BioWhittaker), and 0.085 U/ml
insulin (Novo Nordisk, Bagsvaerd, Denmark). Finally, CB cells were
plated on glass coverslips previously coated with collagen (Sigma) and 1
mg/ml poly-L-lysine (Sigma) and cultured at 37°C in a 5% CO2 incubator
for 24 or 48 h. The culture was fixed with 3% paraformaldehyde in PBS
before the X-gal staining. Subsequently, the immunofluorescence study
was made using a polyclonal anti-TH (1:1000; Pel-Freez) and a mono-
clonal anti-glial fibrillary acid protein (1:300; Sigma) as primary antibod-
ies and an anti-rabbit IgG (Alexa 568, 1:700; Molecular Probes, Eugene
OR) and an anti-mouse fluorescein-conjugated IgG (1:200; Pierce, Rock-
ford, IL) as secondary antibodies.
Carotid body grafting. The general procedure used for intrastriatal CB
grafting in mice was similar to that described previously for rats (Toledo-
Aral et al., 2003). Briefly, CBs were trimmed into pieces approximately
half of the size of the whole organ. Usually two CB pieces were placed on
1 l of Tyrode’s solution and injected into the striatum (stereotaxic
coordinates referenced to bregma, in mm: anteroposterior,0.4; lateral,
2; ventral, 3.5). Sham-operated animals received 1 l of Tyrode’s
solution at the same stereotaxic coordinates.
Electron microscopy. For the electron microscopy study, heterozygous
GDNF/lacZ mice carotid bifurcations and C57BL/6 mice brains grafted
with CBs from heterozygous GDNF/lacZ mice were used. The extraction,
fixation, sectioning, and X-gal staining of the tissue were as described
above (Histological analyses).-Galactosidase-reacted 100-m-thick vi-
bratome sections were fixed overnight with 0.02% glutaraldehyde and
4% paraformaldehyde in PBS and washed several times in PBS. Sections
were thereafter postfixed with 1% osmium tetroxide and 7% glucose in
PBS for 1 h at room temperature, dehydrated in ascending grades of
ethanol, and flat embedded in Araldite resin (Durkupan; Fluka, Neu-
Ulm, Germany) between two acetate sheets. Plastic-embedded sections
were examined with the light microscope, and areas of interest were
excised with a razor blade and glued to an empty Araldite block for
sectioning at 1.5 m in a Reichert Ultracut E ultramicrotome (Leica,
Deerfield, IL). These semithin sections were stained with 1% toluidine
blue and examined in the light microscope, and those containing blue
precipitates characteristic of the -galactosidase reaction were selected
for additional analysis and photographed. Selected semithin sections
were transferred to a resin block and resectioned at 65–70 nm (DeFelipe
and Faire´n, 1982). The thin sections were collected on Formvar-coated
slot grids, stained with uranyl acetate and lead citrate, and examined with
a Jeol (Peabody, MA) JEM-1010 electron microscope.
GDNF ELISA. Tissue GDNF protein content was estimated in samples
obtained from Wistar rats (5–20 weeks old) using a commercial ELISA
kit (GDNF Emax Immunoassay System; Promega, Madison, WI). All of
the tissues were removed and immediately frozen in liquid nitrogen;
afterward, the samples were homogenized using a Polytron (OMNI,
Waterbury, CT). For these studies, we pooled tissues removed from dif-
ferent animals. The total number of samples were as follows: 143 CBs, 14
adrenal medullas (AMs), 12 superior cervical ganglia (SCGs), and 3
Zuckerkandl’s organs. The protein extraction and the ELISA were com-
pleted following the instructions of the manufacturer, except that the
dilutions used of the anti-GDNF monoclonal and anti-hGDNF poly-
clonal antibodies were 1:500 and 1:250, respectively. Absorbance at 450
nm was measured in a plate reader (Thermo Electron Corporation, Van-
taa, Finland). A separate procedure was followed to measure the release
of GDNF from dissociated CB, adrenal medulla, and pheochromocy-
toma rat PC12 cells. Primary culture of dissociated Wistar rat [postnatal
day 10 (P10) to P13] CB cells was performed as described above for mice
but without insulin. Dispersed chromaffin cells were also obtained from
adrenal glands of Wistar rats (P10 –P13) that, after removal, were minced
with standard razor blades. The pieces of adrenal glands were placed in
extraction solution (in mM: 154 NaCl, 5.6 KCl, 11 glucose, and 10
HEPES, pH 7.4) with 0.6 mg/ml collagenase type IA (Sigma) and 1.3
mg/ml bovine serum albumin (Sigma) and incubated at 37°C for 30 min
with mechanical dispersion every 10 min. After dissociation, the cell
suspension was centrifuged at 200 g at 4°C for 5 min. The supernatant
was removed, and the pellet was resuspended in PBS containing 0.6
mg/ml collagenase type IA (Sigma) and 0.3 mg/ml trypsin (Sigma) and
incubated at 37°C for 10 min. Enzymes were washed with a solution
containing 2 vol of DMEM (Invitrogen), 10% fetal bovine serum (Bio-
Whittaker), 1% penicillin/streptomycin (BioWhittaker), and 1%
L-glutamine (BioWhittaker). After washing the enzymatic solution, the
cells were plated using the same media. PC12 cells were cultured as de-
scribed by Toledo-Aral et al. (1995). The release of GDNF from the
cellular preparations was measured by a modification of the ELISA in situ
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method described previously for BDNF detection (Balkowiec and Katz,
2000). Briefly, 96-well ELISA plates were UV sterilized for 30 min and coated
with an anti-GDNF monoclonal antibody (Promega) overnight at 4°C. The
plates were washed and blocked, followed by two 1 h incubations with cul-
ture medium to remove any residue of the ELISA washing solutions. Primary
cultures of CB, AM, and PC12 cells were placed in the pretreated plates
(1.2–5 104 cells per well) and cultured for 48 h. GDNF samples used to
generate the standard curve were diluted in culture medium and incubated
in the same plates. After 48 h in culture, cells were washed, and the ELISA was
performed as described above for the studies of tissue GDNF protein con-
tent. ELISA results are given as mean SEM. The
statistical significance of differences among pa-
rameters was considered at a value of p  0.05
(Student’s t test).
Results
Selective expression of GDNF in CB
glomus cells of adult rodents
GDNF is expressed in several tissues dur-
ing development, and its presence in the
embryonic and newborn CB has been re-
ported previously (Nosrat et al., 1996; Lip-
ton et al., 1999; Erickson et al., 2001).
However, unequivocal evidence for GDNF
expression in CB of adult rodents was ob-
tained from heterozygous knock-out
GDNF/lacZ mice, in which the cells ex-
pressing GDNF contain -galactosidase
deposits that can be labeled with the char-
acteristic blue X-gal staining (Toledo-Aral
et al., 2003). Using this experimental tool,
we compared the level of GDNF expres-
sion in the CB and that in the AM, SCG, or
retina, which are catecholaminergic donor
tissues used in transplantation studies to
treat PD in animals and humans (Bohn et
al., 1987; Itakura et al., 1988; Yurek and
Sladek, 1990; Rosenthal, 1998). The histo-
logical illustrations in Figure 1 clearly
show the high level of GDNF expression in
the CB (blue– green color deposits in A)
and its complete absence in the AM (C,D),
SCG (E, F), and retina (G, H). As control,
we also show the lack of X-gal deposits in a
CB from a wild-type animal (B). Counter-
staining with anti-TH antibody demon-
strated the typical organization in clusters
of CB glomus cells (A, B, insets), the TH-
positive cells in the AM and SCG (C, E,
insets), and the dopamine-containing am-
acrine cells of the retina (G). Similar com-
parative histological analysis was per-
formed in 25 animals (aged between 1 and
17.5 months) with identical results. In four
newborn (P1) animals studied (two /
and two /), GDNF expression was
found to be high in the CB, absent in AM
and SCG, and small in the retina (data not
shown). Although these results clearly in-
dicated that the adult CB expresses more
GDNF that any other tissue tested, we di-
rectly measured the amount of GDNF pro-
tein in tissue extracts from adult rats (1–5
months of age) using a conventional
ELISA detection method. GDNF content
in CB was one order of magnitude higher than in AM, SCG, or the
organ of Zuckerkandl, whose contents were barely detectable or
below the level of resolution of the technique (Fig. 2A). The
organ of Zuckerkandl, a tissue structurally related to the adrenal
medulla, was included in the study because it has been reported
recently to induce recovery caused by GDNF release when trans-
planted in the striatum of parkinsonian rats (Espejo et al., 2001).
Besides the differences in GDNF synthesis and storage, CB cells
Figure 1. Selective GDNF expression in adult carotid body. A, GDNF expression in the carotid body (blue–green dots) evi-
denced by X-gal staining in heterozygous GDNF/lacZ mice (17.5 months old). The inset shows the typical glomerular structure of
the CB after TH immunohistological staining.B, CB section from awild-type animal with complete absence of X-gal labeling after
staining (8.5months of age). The inset shows again the typical glomerular structure of the sameCB.C–H, Lack of GDNF expression
in the adrenalmedulla (C,D; 5months of age), superior cervical ganglion (E,F; 5months of age), and retina (G,H; 7months of age)
of heterozygous GDNF/lacZ mice after X-gal staining. To confirm the stability of the tissues, the insets in C, E, and G show,
respectively, the characteristic TH-positive immunostaining of adrenal medulla chromaffin cells, superior cervical ganglion neu-
rons, and retinal amacrine cells of the samemice.
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were also able to release more GDNF than any other cell type
studied. This was demonstrated by using a highly sensitive in situ
GDNF ELISA that allowed to measure GDNF secreted to the
extracellular media by CB and other paraneural cultured cells
(Fig. 2B).
To identify the source of GDNF produced in the mouse CB,
the organs were enzymatically treated and cells were mechani-
cally dispersed. The cells analyzed with the characteristic X-gal
deposits (n  151) were 10 m in diameter and appeared
strongly stained with the anti-TH antibody but unreactive to the
GFAP antibody, thus indicating that they were dopaminergic
type I, or glomus, cells (Fig. 3A–C). In contrast, the subtentacular,
glial-like type II cells, the second most abundant cell class in the CB
(n 73), were TH negative and GFAP positive but did not contain
X-gal inclusions (Fig. 3D–F). Electron microscopy analysis further
demonstrated the presence of X-gal deposits in the cytoplasm of
glomus cells, which were identified by the characteristic large nu-
cleus with fragmented chromatin and abundant dense-core cyto-
plasmic secretory vesicles apposed close to the membrane (Fig. 3G–
I). Because GDNF was originally cloned from a glial cell line (Lin et
al., 1993) and it is expressed in some glial cells in the adult brain,
GDNF in the CB was thought to be expressed by subtentacular cells,
thus exerting a trophic action on glomus cells (Luquin et al., 1999;
Toledo-Aral et al., 2002, 2003). The results described here indicate
that, unexpectedly, dopaminergic glomus cells are those responsible
for the synthesis of GDNF.
GDNF expression in glomus cells of intrastriatal CB grafts
Because a major goal of this work was to evaluate the suitability of
CB tissue for cell therapy, we tested to see whether the ability of
CB cells to express GDNF is maintained after striatal transplan-
tation. CBs from heterozygous GDNF/lacZ animals (1–2 months
old) were transplanted into normal littermates (2–3 months old;
n 7), and the striatum was studied 0.5– 4 months after grafting.
As shown in Figure 4A, typical ovoid-shaped CB transplants with
intense X-gal staining were seen in the striatum of the trans-
planted animals. Counterstaining with antibodies against TH
showed that X-gal deposits were maintained in transplanted glo-
mus cells (Fig. 4B) with an appearance remarkably similar to that
of the normal CB (Fig. 4C). We observed a slight increase in
GDNF expression in the grafted CB cells that could be attributed
to their activation by the hypoxic conditions in the brain paren-
chyma. Nevertheless, this phenomenon was not studied in detail.
Electron microscopy analysis on CB grafts confirmed the pres-
ence of intense X-gal deposits in the cytoplasm of transplanted
glomus cells, which had typically large nucleus and fragmented chro-
matin (Fig. 4D–F). Noticeably, the clusters of dense-core vesicles
Figure 2. GDNF protein content and release in CB compared with other TH-positive prepa-
rations. A, GDNF levels (in picograms per milligram) measured by standard ELISA in rat tissues.
The number of separate measurements was as follows: six CBs, six SCGs, eight AMs, and three
Zuckerkandl’s organs (Zuck).B, GDNF release (picograms per 10 4 cells in 24 h)measured by the
ELISA in situ assay from dispersed carotid body, adrenal medulla, and PC12 cells. Data are from
six CB, four AM, and four PC12 different cultures in three independent experiments. The statis-
tical significance of differences among parameters was considered at *p 0.05 (see Materials
and Methods).
Figure 3. GDNF expression in CB glomus cells. A–C, GDNF expression (blue precipitate, A) in
a typical dispersed CB glomus cell that was TH positive (B, red fluorescence) but GFAP negative
(C).D–F, Lack of GDNF (D) and TH (E) expression in a representative dispersed subtentacular CB
cell. Green fluorescence in F indicates that the cell was GFAP positive. The cells are examples
obtained from primary cultured CB cells removed from heterozygous GDNF/lacZ mice. Cultures
were subjected to X-gal staining and simultaneous TH and GFAP immunofluorescent detection.
G–I, Ultrastructural analysis of a CB from a 6-month-old heterozygous GDNF/lacZ mouse after
-galactosidase reaction. The blue asterisks (H, I ) indicate the specific localization of the X-gal
deposits within glomus cells (see the correspondence with the blue staining indicated by ar-
rowheads in the semithin section in G). CB glomus cells are clearly identified by the character-
istic large nucleus with fragmented chromatin (G–I ).
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located nearby the membrane, which are characteristic of glomus
cells in situ (Fig. 3I), were not observed in transplanted glomus cells,
suggesting that, after denervation, there is a progressive decrease in
the number of synaptic-like clustering of catecholaminergic secre-
tory vesicles. Indeed, in glomus cells examined only 15 d after graft-
ing, the dense-core vesicles appeared already
dispersed over the cytosol (Fig. 4G).
Several authors have suggested that
striatal reinnervation could be either in-
duced simply by brain injury or gliosis (Ho
and Blum, 1997; Song and Haber, 2000) or
a consequence of nonspecific tissue-
induced neurotrophism (Yurek and
Sladek, 1990). It has also been postulated
that macrophages activated after rupture
of the brain– blood barrier in intracerebral
grafts can produce neurotrophic factors
and induce axonal sprouting (Batchelor et
al., 1999). Although the lack of striatal re-
innervation in the sham-operated parkin-
sonian animals (Espejo et al., 1998; Luquin
et al., 1999; Hao et al., 2002; Toledo-Aral et
al., 2003; Shukla et al., 2004) have already
demonstrated the specificity of CB graft ef-
fects, we wondered whether GDNF is up-
regulated in brain parenchyma or in mac-
rophages after CB grafting and/or brain
damage. To address this question, we per-
formed CB (from 1- to 2-month-old wild-
type donors) or sham transplants in host
heterozygous GDNF/lacZ animals (2–3
months old). Figure 5A shows a large in-
trastriatal CB transplant with numerous
glomeruli of immunostained TH-positive
glomus cells. The typical blue X-gal depos-
its in the host ipsilateral striatum are
marked by arrowheads. Note that these de-
posits do not accumulate in the proximity
of the graft and that their appearance and
density were similar in the contralateral
striatum (Fig. 5B). No indication of GDNF
expression were seen within cells in the
substantia nigra of either sham-operated
or CB-transplanted animals. These obser-
vations indicate that the CB transplant did
not induce GDNF upregulation in the host
nigrostriatal brain parenchyma. In sham-
operated heterozygous GDNF/lacZ ani-
mals, abundant macrophages with the
characteristic bright yellowish color were
often seen along the needle tract (Fig. 5C,
large arrows). In none of the animals stud-
ied (n  3) did these macrophages (be-
longing to the host brain) show any sign of
GDNF expression, whereas X-gal deposits
were clearly observed in the neighboring
striatum (Fig. 5C, small arrowheads).
These results strongly suggest that striatal
GDNF production is not significantly up-
regulated after CB grafting and that brain
injury does not induce by itself an obvious
increase in GDNF production by either
macrophages or parenchymal brain cells.
GDNF expression in CB of aged and parkinsonian animals
Autotransplantation of CB tissue produces notable clinical re-
covery in some PD patients, but it has little effect in others (Ar-
jona et al., 2003). The variables that determine the clinical out-
Figure 4. GDNF expression in intrastriatally grafted CB glomus cells. A, GDNF expression (blue X-gal staining) in a 1 month
intrastriatal CB transplant (from a 2-month-old heterozygous GDNF/lacZmouse) grafted into a 4-month-oldwild-typemouse.B,
C, Comparison of GDNF (green dots) and TH (light brown) expression and general phenotypic appearance of an intrastriatal CB
graft (B; 1.5 months after transplantation) and a CB in situ (C; removed from a 5-month-old animal). In both cases, the tissues
belong to heterozygous GDNF/lacZ mice. D–F, Ultrastructural analysis of the same CB graft shown in A. The arrowhead in the
semithin section (D) and the pictures (E, F ) indicates the correspondent X-gal deposit, showing the GDNF expression in grafted CB
glomus cells.G, Ultrastructural analysis of a 15-d-old graft showing a typical CBglomus cellwith somedense-core vesicles that are
dispersed throughout the cytoplasm. CB glomus cells in D–G are clearly identified by the characteristic large nucleus with
fragmented chromatin.
Figure 5. Absence of endogenous striatal GDNF induction by CB grafting or nonspecific brain damage. A, B, Heterozygous
GDNF/lacZ mice striatal sections ipsilateral (A) and contralateral (B) to a CB graft from a 1-month-old wild-type donor. Arrow-
heads indicate the presence of X-gal deposits (GDNF expression) in the host tissue, whichwas similar in the two sides of the brain.
C, Heterozygous GDNF/lacZ mice striatal section of a sham-operated animal. Note the absence of X-gal deposits (indicating the
lack of GDNF expression) within the bright yellowish macrophages (arrows) along the needle tract. However, X-gal deposits are
clearly seen in the neighboring parenchyma. TH immunohistochemistry was performed in all sections after the X-gal staining.
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come of CB autografts in PD are, at present, unclear, but patient
age and advanced parkinsonism could be important limiting fac-
tors (Arjona et al., 2003). Therefore, we decided to evaluate in the
rodent model whether the CB ability to synthesize GDNF is affected
by age or the chronic administration of neurotoxins that destroy
mesencephalic dopaminergic neurons. Interestingly, the average
number of X-gal deposits per CB increased almost threefold in old
mice (aged between 13 and 17.5 months) when compared with
young adults (aged between 2 and 4.5 months) (Fig. 6A). This dif-
ference in GDNF expression was a consequence of the organ growth
with age (Fig. 6B). We also investigated CB GDNF production in
chronically MPTP-treated mice compared with sham-treated litter-
mates. GDNF expression, as determined by the number of X-gal
inclusions, was not reduced by MPTP (Fig. 6C). Surprisingly,
chronic application of the toxin increased the number of X-gal de-
posits. MPTP-induced parkinsonism in the same animals was con-
firmed by the marked decreased in the number of dopaminergic
nigra neurons (Fig. 6D). These experiments indicate that the activity
of the CB GDNF promoter (and so the ability to express GDNF) is
maintained intact along the mouse adult life. They also show that CB
GDNF expression is resistant to neurotoxins capable of producing
parkinsonism in mice and primates.
Discussion
Neurotrophic factors have become in recent years a therapeutic
promise for brain repair in neurodegenerative diseases or after
ischemia and trauma. Among these factors, GDNF has received
special attention because of its potent effects on dopaminergic
neurons (Lin et al., 1993). Exogenous GDNF also protects neu-
rons from death after transient brain ischemia or in Huntington
models (Araujo and Hilt, 1997; Miyazaki et al., 1999; Alberch et
al., 2002), supports the survival of axotomized spinal and corti-
cospinal motoneurons (Henderson et al., 1994; Giehl et al., 1998;
Yuan et al., 2000), and retards toxic and hereditary Purkinje cell
degeneration (McAlhany et al., 1997; Tolbert and Clark, 2003). In
this article, we show that, besides being highly dopaminergic, CB
glomus cells contain more GDNF than any other structure stud-
ied in the adult rodent and that the ability to synthesize GDNF is
maintained in the CB of aged animals or after chronic MPTP
treatment. Moreover, the production of high levels of GDNF is
maintained in long-term intrastriatal CB grafts. Therefore, neu-
roprotection in PD and other pathological conditions could be
achieved through delivery of GDNF by CB glomus cells trans-
planted in brain parenchyma or neuronal targets.
Most of our experiments were done with the GDNF/lacZ mouse,
in which the activity of the GDNF promoter leads to the synthesis of
-galactosidase. Deposits of the enzyme are revealed by a simple
histochemical (X-gal) reaction (Sa´nchez et al., 1996; Toledo-Aral et
al., 2003). This technique sets a high threshold for the identification
of GDNF-producing cells, because the formation of the characteris-
tic X-gal cytosolic inclusion possibly requires high concentrations of
the enzyme. Nevertheless, we found it to be an excellent and repro-
ducible tool for the semiquantitative comparison of GDNF produc-
tion among different tissues and a method with low susceptibility to
experimental artifacts. Even in the CB, naturally expressed trophic
factors are present at a level below that required for obvious detec-
tion with the classical immunocytochemical methods, which, at least
in our hands, often yield false-positive results. It could be argued that
the presence of cytosolic -galactosidase deposits does not actually
represent the activity of the GDNF promoter if, after being formed,
they remain stable for long time periods. This does not seem to be the
case because, in our heterozygous GDNF/lacZ animals, X-gal inclu-
sions in cells of the neonatal retina disappeared after 1 or 2 weeks of
postnatal life. The ability to express GDNF in adult glomus cells was
also evident because X-gal deposits increased in number with age
and after MPTP treatment. Furthermore, we also observed that the
number of X-gal deposits in freshly dissociated glomus cells is lower
than in the in situ CBs, probably as a consequence of the dispersion
trauma. However, the X-gal deposits reappear if the cells are allowed
to recover in culture for 48 h, thus indicating a relatively fast turnover
of the -galactosidase protein (data not shown). Moreover, GDNF
expression in the CB and other tissues estimated with X-gal staining
in the lacZ mouse was in excellent agreement with the results ob-
tained in adult rats, in which we measured the GDNF content and
the amount released to the media using conventional and in situ
ELISA immunodetection methods.
The dopaminergic nature of CB glomus cells and their ability
to synthesize and release GDNF in large amounts make them
optimally suited for cell therapy. Studies on animal models have
shown that intracerebral application of exogenous GDNF can
ameliorate parkinsonism. However, the amount of GDNF and
the method of delivery are issues subjected to debate. Although
other routes have been used, GDNF appears to yield best effects
when delivered into the striatum, the target for nigral dopami-
nergic axons (Kirik et al., 2000). Among the different strategies
Figure 6. Maintenance of CB GDNF expression in aged and parkinsonianmice.A, Increase of
GDNF expression (ordinate; estimated by the number of X-gal deposits per CB) in old heterozy-
gous GDNF/lacZmice (13–17.5months of age) comparedwith young adults (2– 4.5months of
age).B, Similar data as inA but normalized to the CB volume. C, Increase of CB GDNF expression
in chronic MPTP-treated mice compared with saline-treated littermates. In the same animals,
the application of MPTP induced a clear reduction in the number of TH-positive nigral neurons
(D). The number of experiments is indicated in parentheses. The statistical significance of dif-
ferences among parameters was considered at *p 0.05 (see Materials and Methods).
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for GDNF application are the intraparenchymal bolus injection
of the protein (Tomac et al., 1995; Gash et al., 1996; Bjo¨rklund et
al., 1997; Rosenblad et al., 1998; Grondin et al., 2002) and the
injection of engineered neural cell lines (Akerud et al., 2001) or
replication-deficient viruses (Choi-Lundberg et al., 1997; Mandel
et al., 1997; Kirik et al., 2000; Kordower et al., 2000; Bensadoun et
al., 2003) expressing GDNF. These procedures are for safety rea-
sons currently unpractical in humans. Monthly bolus injection of
GDNF into the ventricles has been shown to be ineffective to
ameliorate PD patients. Furthermore, numerous side effects were
reported (Nutt et al., 2003), and there was no evidence of striatal
dopaminergic reinnervation in a subject postmortem (Kordower
et al., 1999). In contrast, direct and continuous infusion of GDNF
into the putamen of PD patients has yielded significant clinical
improvement in a safety trial (Gill et al., 2003). However, prelim-
inary results of an independent double-blind placebo-controlled
study, using the same method of GDNF delivery, are less favor-
able (Dingwell, 2004). Thus, continuous infusion of exogenous
GDNF appears to depend on yet uncontrolled variables that in-
fluence the clinical outcome. Among these variables are the local
changes of pressure, which could cause modifications unrelated
with the neurotrophic effect of the protein, or the amount of GDNF
being released, because it is known that excessive striatal GDNF ex-
pression produces downregulation of TH and aberrant axonal
sprouting in downstream brain areas (Georgievska et al., 2002;
Rosenblad et al., 2003). Intrastriatal grafting of CB tissue has been
shown to produce notable dopaminergic reinnervation and behav-
ioral recovery in parkinsonian rats (Espejo et al., 1998; Hao et al.,
2002; Toledo-Aral et al., 2002, 2003; Shukla et al., 2004) and mon-
keys (Luquin et al., 1999). In rodents, CB grafts are maintained sta-
ble, with metabolically active dopamine- and GDNF-producing glo-
mus cells for the entire animal lifespan. Therefore, glomus cells are
ideal candidates to be used as biological pumps for the controlled
endogenous release of GDNF and probably other trophic factors
with unique synergistic actions. In fact, CB tissue contains BDNF
(Erickson et al., 2001), and CB grafting has also been shown to re-
duce neuronal death in an acute rat stroke model (Yu et al., 2004). A
limitation for the clinical use of glomus cell autotransplants in PD
might be the small size of the CB, which probably synthesizes less
GDNF than is necessary for advanced PD patients (Arjona et al.,
2003). However, this could be circumvented by the generation of
glomus cell-like elements using adult stem cells or precursors ad-
ministered at earlier stages of the disease.
From a physiological viewpoint, it is rather interesting that,
among the cells of the sympathoadrenal lineage studied in adult
rodents, glomus cells are those with higher capacity of GDNF syn-
thesis. The level of GDNF expression in the CB appears to be also
much higher than in the brain areas or paraneural tissues in which
the trophic factor has been detected (Choi-Lundberg and Bohn,
1995; Trupp et al., 1995, 1997; Pochon et al., 1997). So, an obvious
question that arises relates to the functional role of GDNF in the CB.
Although the answer to this question is outside the scope of this
paper, it is worth mentioning that GDNF is upregulated in response
to brain toxic or ischemic damage (Schmidt-Kastner et al., 1994; Abe
and Hayashi, 1997; Hida et al., 2003). We also shown that chronic
systemic application of MPTP, sufficient to produce destruction of
SN neurons, induces GDNF expression in glomus cells. Therefore, a
plausible hypothesis is that, in glomus cells adapted to high environ-
mental oxygen tensions in physiological conditions, the autocrine or
paracrine action of trophic factors, as GDNF, is necessary to protect
from oxidative stress.
Another interesting observation in our work relates to the possi-
ble activation of nonspecific sources of GDNF after brain injury. It
has been suggested that dopaminergic striatal axonal sprouting can
be induced either by brain injury and reactive astrocytes (Ho and
Blum, 1997; Song and Haber, 2000) or by macrophage and microglia
activation (Batchelor et al., 1999). Although expression of small
amounts of GDNF by these cells cannot be discarded, our experi-
ments using the GDNF/lacZ mouse clearly indicate that production
of GDNF by host cells (astrocytes, microglia, or macrophages) is
below the resolution of the X-gal detection method and clearly
present in the CB tissue grafted into the striatum.
In conclusion, dopaminergic CB glomus cells are the elements
studied with the higher capacity to produce GDNF in the adult
rodent. This striking property is stably maintained after trans-
plantation into the striatum. The clinical applicability of glomus
cells to treat PD and possibly other neuropathological conditions
should receive serious attention because they are, in principle,
ideal devices for the endogenous long-term delivery of trophic
factors in the brain parenchyma.
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